Promomed Group of Companies has registered a new antitumor drug for the treatment of common cancers

Promomed's oncological portfolio has been replenished with a new drug for the treatment of common forms of colorectal cancer.

Promomed Group of Companies has registered a powerful broad-spectrum antibiotic

Promomed Group of Companies has registered a powerful broad-spectrum antibiotic

Promomed Company has registered a new anticancer drug for the treatment of the most common types of cancer

The advantages of the innovative Brainmax® drug from Promomed Group were discussed by the participants of the Neuroforum

Efavirenz is a new drug for the treatment of HIV infection in the Promomed Group's drug portfolio

Promomed's Modelform® is the winner of the Smartpharma® Awards 2022

Sorafenib is a new drug in Promomed Group's cancer portfolio

Promomed Group's oncological portfolio has been replenished with a new drug for the treatment of blood cancer

Skyvira® is a generation 2.0 anticoid drug

Russian medicine has received an innovative neuroprotector

Promomed Group of Companies has replenished its portfolio with a new drug for the treatment of HIV infection

Promomed Group of Companies replenished its onco portfolio with a new drug for lung cancer therapy

Promomed Company replenished its onco portfolio with a new drug for prostate cancer therapy

Promomed Group's drugs are included in the new version for the prevention and treatment of COVID-19

Brainmax® is a new neuroprotection technology from Promomed Group of Companies

Esperavir® (molnupiravir) has started to enter the healthcare system, including pharmacies

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office